If your mood becomes much harder to manage before a period and then noticeably improves, the timing is worth taking seriously. That does not make every difficult week PMDD, and it does not mean you should have to tolerate severe symptoms because they are cyclical.
Premenstrual syndrome, or PMS, can involve both physical and emotional symptoms. Premenstrual dysphoric disorder, or PMDD, is a more specific diagnosis involving prominent mood symptoms and significant disruption to daily life. A symptom list alone cannot tell you which explanation fits. Office on Women's Health: PMDD.
Timing matters as much as the symptom
Irritability, low mood, anxiety, changes in appetite, poor sleep or difficulty concentrating can occur for many reasons. With a premenstrual disorder, clinicians look for a recurring relationship to the menstrual cycle, with symptoms appearing before menstruation and easing afterward. They also ask whether work, relationships or usual activities are affected. RCOG guidance on PMS.
PMDD assessment includes a defined combination of symptoms, including a core mood symptom, and consideration of other conditions. It is not diagnosed by having one unusually irritable day or a low wellbeing score. The Office on Women's Health describes a threshold of five or more symptoms, but the pattern, impairment and clinical assessment are essential parts of the diagnosis. PMDD diagnostic overview.
Another possibility is premenstrual exacerbation: an existing problem, such as depression or anxiety, is present across the month and becomes worse before menstruation. That distinction changes the treatment conversation because the underlying problem may need care throughout the cycle. ISPMD consensus on premenstrual disorders.
Why daily records are more useful than remembering the worst week
A clinician may ask for daily symptom ratings across at least two consecutive cycles. Recording symptoms as they happen helps show whether there is a consistent pattern and whether better days are genuinely different. If the first two cycles disagree, more observation may be useful. This is an assessment method, not a reason to delay an appointment. ISPMD assessment recommendations.
The Daily Record of Severity of Problems, or DRSP, is one established instrument. Original validation studies found that it could reliably capture relevant symptoms and impairment and was sensitive to treatment changes. Those findings apply to that instrument; they do not validate every mood diary or PsychPod's scores for diagnosing PMDD. Endicott and colleagues, DRSP validation.
For a practical appointment note, you could record:
- The date and whether bleeding occurred.
- Mood symptoms and how strong they were, including on better days.
- Sleep and physical symptoms.
- Effects on work, study, relationships or basic tasks.
- Medication or hormonal-contraception changes that might affect interpretation.
Use a consistent, brief approach rather than rebuilding the diary from memory at the end of the month. If your clinician recommends a particular scale, follow that format. A personal journal can add context, but you do not need to share more private detail than is relevant to your care.
What treatment research actually shows
SSRIs are among the treatments with the strongest research support. A 2024 Cochrane review included 34 randomized trials involving 4,563 participants with PMS or PMDD. SSRIs probably reduced self-reported premenstrual symptoms, with overall moderate-certainty evidence. Nausea, reduced energy, sleep difficulties and sexual side effects were among the adverse effects reported. Poor reporting and suspected publication bias limit confidence in the exact size of benefit. Cochrane review of SSRIs.
Some prescribed regimens are continuous; others target part of the cycle. Studies support both approaches, and evidence comparing them is not completely consistent. The Cochrane review favored continuous treatment in subgroup analyses, while a direct-comparison review did not find a statistically significant difference. This is a decision for the prescriber and patient, not a reason to change a medication schedule independently. Reilly and colleagues, intermittent versus continuous SSRIs.
Certain hormonal contraceptives are another option. A 2023 Cochrane review of five trials involving 858 participants, mostly with PMDD, found that drospirenone combined with ethinylestradiol may improve symptoms and functioning. Benefits were small to moderate, adverse effects and withdrawals were more common, and effectiveness beyond three cycles was uncertain. The findings cannot be generalized to every contraceptive formulation, and these trials cannot rule out rare serious harms. Cochrane review of drospirenone-containing contraceptives.
Supportive habits can complement care
Regular meals, manageable physical activity, sleep routines and support with stressful demands can be useful parts of a care plan. CBT is another option to discuss. These approaches should not become a test of whether you have tried hard enough before receiving treatment. RCOG recommends considering a range of options and reviewing what actually helps. RCOG management guidance.
Be cautious with products marketed as “hormone balancing.” That phrase does not establish a diagnosis, explain your symptoms or show that a product works. Check supplements with a pharmacist or clinician, particularly if you take other medicines or use hormonal contraception. Different treatments can have different risks depending on your medical history.
When to seek help
Arrange an appointment if the pattern repeatedly disrupts your life, symptoms are severe, or low mood and anxiety extend beyond the premenstrual part of the cycle. You can begin recording symptoms while waiting. You do not need to finish two cycles before asking for care.
Sources and further reading
- Office on Women's Health. Premenstrual dysphoric disorder, updated 2025.
- RCOG. Managing premenstrual syndrome, 2018, currently under review.
- Nevatte T and colleagues. ISPMD consensus on the management of premenstrual disorders, Archives of Women's Mental Health, 2013.
- Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems: reliability and validity, Archives of Women's Mental Health, 2006.
- Jespersen C and colleagues. SSRIs for PMS and PMDD, Cochrane, 2024.
- Reilly TJ and colleagues. Intermittent SSRIs for premenstrual syndromes: a systematic review and meta-analysis, Journal of Psychopharmacology, online 2022.
- Ma S, Song SJ. Oral contraceptives containing drospirenone for PMS, Cochrane, 2023.
Related reading: Understanding irritability and perimenopause, sleep and mood.
Evidence checked 5 September 2026. General education, not a diagnostic test or instructions for changing treatment.